Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$2.03 | -$2.03 | -$2.03 |
| Q2 2025 | 3 | -$2.01 | -$1.44 | -$1.73 |
| Q3 2025 | 1 | -$1.08 | -$1.08 | -$1.08 |
| Q4 2025 | 1 | -$0.74 | -$0.74 | -$0.74 |
| Q1 2026 | 1 | -$1.20 | -$1.20 | -$1.20 |
| Q2 2026 | 1 | -$1.20 | -$1.20 | -$1.20 |
| Q3 2026 | 1 | -$1.50 | -$1.50 | -$1.50 |
| Q4 2026 | 1 | -$1.50 | -$1.50 | -$1.50 |
IN8bio, Inc. last posted its earnings results on Thursday, November 6th, 2025. The company reported $-0.85 earnings per share for the quarter, topping analysts' consensus estimates of $-1.2 by $0.35. The company had revenue of 0 for the quarter and had revenue of 0 for the year. IN8bio, Inc. has generated $-1 earnings per share over the last year ($-0.57 diluted earnings per share) and currently has a price-to-earnings ratio of -0.39. IN8bio, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | -$1.20 | -$0.85 | 0.35 | $5.80 M | $0 |
| 08/07/2025 | Q2 2025 | -$1.50 | -$1.24 | 0.26 | $0 | $0 |
| 05/07/2025 | Q1 2025 | -$1.80 | -$0.07 | 1.73 | $0 | $0 |
| 03/13/2025 | Q4 2024 | -$0.07 | -$0.09 | -0.02 | $0 | $0 |
| 11/12/2024 | Q3 2024 | -$0.14 | -$0.15 | -0.01 | $0 | $0 |
| 08/08/2024 | Q2 2024 | -$0.16 | -$0.19 | -0.03 | $0 | $0 |
| 05/09/2024 | Q1 2024 | -$0.17 | -$0.20 | -0.03 | N/A | $0 |
| 03/14/2024 | Q4 2023 | -$0.16 | -$0.21 | -0.05 | N/A | $0 |
| 11/09/2023 | Q3 2023 | -$0.25 | -$0.23 | 0.02 | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$0.28 | -$0.27 | 0.01 | N/A | $0 |
| 05/12/2023 | Q1 2023 | -$0.33 | -$0.30 | 0.03 | N/A | $0 |
| 03/30/2023 | Q4 2022 | -$0.28 | -$0.32 | -0.04 | N/A | $0 |
| 11/10/2022 | Q3 2022 | -$0.28 | -$0.34 | -0.06 | N/A | $0 |
| 08/12/2022 | Q2 2022 | -$0.33 | -$0.38 | -0.05 | N/A | $0 |
| 05/12/2022 | Q1 2022 | -$0.34 | -$0.33 | 0.01 | N/A | $0 |
| 03/17/2022 | Q4 2021 | -$0.21 | -$0.31 | -0.1 | N/A | $0 |
| 11/10/2021 | Q3 2021 | -$0.33 | -$0.18 | 0.15 | N/A | $0 |
| 09/10/2021 | Q2 2021 | -$0.30 | -$0.16 | 0.14 | N/A | $0 |
| 03/31/2021 | Q1 2021 | N/A | -$0.12 | N/A | N/A | $0 |
| 12/31/2020 | Q4 2020 | N/A | -$0.12 | N/A | N/A | $0 |
IN8bio, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based offlast year's report dates.
In the previous quarter, IN8bio, Inc. (:INAB) reported $-0.85 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.2 by $0.35.
The conference call for IN8bio, Inc.'s latest earnings report can be listened to online.
The conference call transcript for IN8bio, Inc.'s latest earnings report can be read online.
IN8bio, Inc. (:INAB) has a recorded net income of $-30,437,000.IN8bio, Inc. has generated $-0.57 earnings per share over the last four quarters.
IN8bio, Inc. (:INAB) has a price-to-earnings ratio of -0.39 and price/earnings-to-growth ratio is 0.01.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED